IRVINE, Calif., April 29 /PRNewswire/ -- Abraxis BioScience initially engaged LCS Constructors, Inc. to perform an evaluation of the former ICN/Valient Pharmaceutical building in Costa Mesa, California prior to their purchasing this 165,000 square foot building.

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr.

Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

Abraxis BioScience, Inc.

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the establishment of a global leadership team with newly created positions that strengthen the company's international senior leadership and build a worldwide commercialization platform for growth.